Chart-Typ:
Zeitraum:
| Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA | Total revenue increased 60% year over year to $6.4 millionNet loss per share decreased 88% compared to the prior-year quarterGross margin expanded to 40% as operating expenses remained stableFDA clearance... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn Wound Irrigation Solution | BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k)... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 | As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's two commercialized... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog | Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI... ► Artikel lesen |
| Jaguar Health, Inc.: Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure Due to Microvillus Inclusion Disease | Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID SAN FRANCISCO, CA /... ► Artikel lesen |
| QXO, Inc. Completes Acquisition of TopBuild Corp. | Deal Expected to Be Substantially Accretive to QXO's Earnings
GREENWICH, Conn.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) today announced it has closed its previously disclosed acquisition of TopBuild... ► Artikel lesen |
| QXO, Inc. and TopBuild Corp. Stockholders Overwhelmingly Approve QXO's Acquisition of TopBuild | GREENWICH, Conn. & DAYTONA BEACH, Fla.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) ("QXO") and TopBuild Corp. (NYSE: BLD) ("TopBuild") today announced that stockholders of both companies overwhelmingly... ► Artikel lesen |
| Jacobs hat ganze Branchen aufgemischt: Ist QXO der nächste Coup? | Brad Jacobs hat mehrfach bewiesen, wie man in zersplitterten Märkten dominante Konzerne formt. Ist QXO der nächste Coup Den vollständigen Artikel lesen ... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NETCAPITAL INC finden Sie auf Wallstreet Online.